Hochschulschrift
HER2 dynamics and EGF-NRG1 shape the response of HER2-targeted therapies in breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Dimensions
-
30 cm
- Extent
-
159 Seiten
- Language
-
Englisch
- Notes
-
Illustrationen, Diagramme
Ruprecht-Karls-University Heidelberg, Dissertation, 2024
- Event
-
Veröffentlichung
- (where)
-
Heidelberg
- (when)
-
[2024]
- Creator
- Contributor
- Table of contents
- Rights
-
Bei diesem Objekt liegt nur das Inhaltsverzeichnis digital vor. Der Zugriff darauf ist unbeschränkt möglich.
- Last update
-
11.03.2025, 12:34 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Object type
- Hochschulschrift
Time of origin
- [2024]
Other Objects (12)
Photoimmunotherapy of HER2-expressing Breast Cancer Cells
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
EGFR Expression in HER2-Driven Breast Cancer Cells
Exploring combination treatment with a HER2 and a Pirin inhibitor in HER2-overexpressing breast cancer cells
Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
Biomarker potential of extracellular microRNA expression signatures in breast cancer under HER2-targeted therapy
Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases
Häufigkeit der EGFR- und HER2-Ausprägung sowie HER2-Genamplifikation beim Gallengangskarzinom
Einfluss von HER2 auf EGF-Rezeptor-vermittelte Signaltransduktion und Migration in humanen Glioblastomzelllinien
Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells
Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
Targeted Intraoperative Radiotherapy Tumour Bed Boost during Breast-Conserving Surgery after Neoadjuvant Chemotherapy - a Subgroup Analysis of Hormone Receptor-Positive HER2-Negative Breast Cancer
Photoimmunotherapy of HER2-expressing Breast Cancer Cells
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
EGFR Expression in HER2-Driven Breast Cancer Cells
Exploring combination treatment with a HER2 and a Pirin inhibitor in HER2-overexpressing breast cancer cells
Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
Biomarker potential of extracellular microRNA expression signatures in breast cancer under HER2-targeted therapy
Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases
Häufigkeit der EGFR- und HER2-Ausprägung sowie HER2-Genamplifikation beim Gallengangskarzinom
Einfluss von HER2 auf EGF-Rezeptor-vermittelte Signaltransduktion und Migration in humanen Glioblastomzelllinien
Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells
Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
Targeted Intraoperative Radiotherapy Tumour Bed Boost during Breast-Conserving Surgery after Neoadjuvant Chemotherapy - a Subgroup Analysis of Hormone Receptor-Positive HER2-Negative Breast Cancer
Photoimmunotherapy of HER2-expressing Breast Cancer Cells
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
EGFR Expression in HER2-Driven Breast Cancer Cells
Exploring combination treatment with a HER2 and a Pirin inhibitor in HER2-overexpressing breast cancer cells
Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
Biomarker potential of extracellular microRNA expression signatures in breast cancer under HER2-targeted therapy
Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases
Häufigkeit der EGFR- und HER2-Ausprägung sowie HER2-Genamplifikation beim Gallengangskarzinom
Einfluss von HER2 auf EGF-Rezeptor-vermittelte Signaltransduktion und Migration in humanen Glioblastomzelllinien
Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells
Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy